Credit: Getty Images. The approval was based on data from the phase 3 EMPEROR-Reduced trial. The Food and Drug Administration (FDA) has approved Jardiance ® (empagliflozin) to reduce the risk of ...
Heart failure (HF) imposes a large and growing burden on the population, with a prevalence that is projected to increase to more than 8 million adults by 2030. The high risk of morbidity and mortality ...
Results from the Phase 3 VICTOR trial and a pooled analysis of the VICTOR and VICTORIA trials were presented today at the ESC Congress 2025 and simultaneously published in The Lancet VERQUVO was ...
Patients with newly diagnosed heart failure with reduced ejection fraction (HFrEF) commonly have improvements in their LVEF, but that doesn’t mean they can let their guard down, data from a large ...
ENTRESTO The recommendation was based on data from the double-blind, parallel-group, active-controlled phase 3 PARAGON-HF trial. The Food and Drug Administration (FDA)’s Cardiovascular and Renal Drugs ...
"These findings suggest that small variations in the amount of fluid given to a patient with sepsis, or the decision to give less fluid to a patient because they have heart failure, may not have a ...
SOUTH SAN FRANCISCO, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (CYTK) today announced that COMET-HF (Confirmation of Omecamtiv Mecarbil Efficacy Trial in Heart Failure), a ...
ORLANDO, Fla., March 7, 2005 - Beta-blockers, medications that block the action of certain hormones on the heart, can benefit patients with certain serious heart problems such as diastolic heart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results